Sept 29 (Reuters) – Eli Lilly said on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
Brought to you by www.srnnews.com
SRN News — View the original story at SRNNews.com.
